DK144093D0 - - Google Patents

Info

Publication number
DK144093D0
DK144093D0 DK144093A DK144093A DK144093D0 DK 144093 D0 DK144093 D0 DK 144093D0 DK 144093 A DK144093 A DK 144093A DK 144093 A DK144093 A DK 144093A DK 144093 D0 DK144093 D0 DK 144093D0
Authority
DK
Denmark
Application number
DK144093A
Other languages
Danish (da)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK144093A priority Critical patent/DK144093D0/da
Publication of DK144093D0 publication Critical patent/DK144093D0/da
Priority to AU12725/95A priority patent/AU1272595A/en
Priority to PCT/DK1994/000487 priority patent/WO1995017510A1/fr

Links

DK144093A 1993-12-23 1993-12-23 DK144093D0 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DK144093A DK144093D0 (fr) 1993-12-23 1993-12-23
AU12725/95A AU1272595A (en) 1993-12-23 1994-12-22 A method of producing glucagon-like peptide 1
PCT/DK1994/000487 WO1995017510A1 (fr) 1993-12-23 1994-12-22 Procede de production d'un peptide i du type glucagon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK144093A DK144093D0 (fr) 1993-12-23 1993-12-23

Publications (1)

Publication Number Publication Date
DK144093D0 true DK144093D0 (fr) 1993-12-23

Family

ID=8104857

Family Applications (1)

Application Number Title Priority Date Filing Date
DK144093A DK144093D0 (fr) 1993-12-23 1993-12-23

Country Status (3)

Country Link
AU (1) AU1272595A (fr)
DK (1) DK144093D0 (fr)
WO (1) WO1995017510A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
DE122009000079I2 (de) * 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US6461834B1 (en) 1998-11-06 2002-10-08 Bionebraska, Inc. Clostripain catalyzed amidation of peptides
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CN1162446C (zh) * 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
CN1363654A (zh) 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
CA2841097A1 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumine et proteines hybrides g-csf
WO2005003296A2 (fr) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Proteines hybrides d'albumine
AU2003239865A1 (en) 2002-05-24 2003-12-12 Restoragen Inc. Method for universal enzymatic production of bioactive peptides
AU2003243316A1 (en) 2002-05-24 2003-12-12 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
AU2003239863A1 (en) * 2002-05-24 2003-12-12 Restoragen Inc. Method for enzymatic production of glp-1 (7-36) amide peptides
US7829307B2 (en) 2003-11-21 2010-11-09 Nps Pharmaceuticals, Inc. Production of glucagon-like peptide 2
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
CN100429227C (zh) 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin4多肽片段
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
WO2016210384A2 (fr) 2015-06-25 2016-12-29 Synlogic, Inc. Bactéries manipulées pour traiter des maladies métaboliques
WO2017139708A1 (fr) 2016-02-10 2017-08-17 Synlogic, Inc. Bactéries génétiquement modifiées pour traiter la stéatohépatite non alcoolique (shna)
WO2018172921A1 (fr) 2017-03-20 2018-09-27 Lupin Limited Expression et production à grande échelle de peptides
CN113846124A (zh) * 2021-09-26 2021-12-28 康霖生物科技（杭州）有限公司 一种用于糖代谢相关疾病基因治疗的核酸构建体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27885A (da) * 1985-01-22 1986-07-23 Novo Industri As Fremstilling af peptider
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
JPH04501204A (ja) * 1988-08-11 1992-03-05 サイオス　ノバ　インコーポレイテッド 異種タンパク発現を安定させる方法およびそれに使用するベクター
ES2113879T3 (es) * 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5202239A (en) * 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification

Also Published As

Publication number Publication date
AU1272595A (en) 1995-07-10
WO1995017510A1 (fr) 1995-06-29

Similar Documents

Publication Publication Date Title
TW256900B (fr)
DK0605845T3 (fr)
DK0649622T3 (fr)
TW250601B (fr)
TW245859B (fr)
DK0618680T3 (fr)
DK76793D0 (fr)
DK63994A (fr)
EP0686452A4 (fr)
EP0647920A3 (fr)
DK69093D0 (fr)
AU636285B1 (fr)
DK24593D0 (fr)
ECSDI930112S (fr)
DK128793D0 (fr)
ECSDI930096S (fr)
IN186093B (fr)
DK5993A (fr)
ECSDI930100S (fr)
DK122793D0 (fr)
IN182439B (fr)
ECSDI930105S (fr)
IN185942B (fr)
IN176926B (fr)
IN179278B (fr)

Legal Events

Date Code Title Description
A0 Application filed
ATS Application withdrawn